PRNewsWire
20 Nov 2026, 01:45 UTC · 59m ago
Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
Impact · against what's priced in
Boston Scientific's debt issuance to fund the Penumbra acquisition is a neutral-to-slightly-negative event, as it introduces new interest expenses without addressing the core operational struggles the market is currently pricing. For Penumbra, the confirmation of funding for the acquisition serves as a positive catalyst for the deal's closing.
- BSX−0.10
Not in the price yet
- In context
The issuance of $3.0 billion in USD and €4.25 billion in Euro notes introduces significant new interest expenses (up to 5.875%) that will weigh on net income, though this doesn't resolve the operational decelerations the market is currently discounting.





